drugset
drugset / Trial / NCT05227118

Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

NCT05227118 ↗

Phase 1 Completed 29 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.

Timeline

Start
2022-07-01
Primary completion
2023-01-10
Completion
2023-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-8189 Small molecule 16 mg Oral
Subject MK-8189 Small molecule 24 mg Oral

Indications

Alzheimer disease